Treatment of advanced neuroendocrine tumours with the radiolabelled somatostatin analogue octreotide

Gregory A. Kaltsas, Zoe Stefanidou, Dimitris Papadogias, Ashley B. Grossman

Neuroendocrine tumours (NET) have a particular tendency to express functional receptors and/or uptake mechanisms. Radionuclides, such as 111In-pentetreotide, a somatostatin analogue, which bind to somatostatin receptors, present an imaging modality that has been used for both the diagnosis and staging of NET…

Pasireotide for malignant insulinoma

Amit Tirosh, Salomon M. Stemmer, Evgeny Solomonov, Eldad Elnekave, Wolfgang Saeger, Yelena Ravkin, Kobi Nir, Yeela Talmor, Ilan Shimon

Download PDF

Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin analogs octreotide and lanreotide have limited ability to control the hypoglycemic events. Pasireotide is a multi-receptor targeted somatostatin-analog with improved affinity for SSTR5. There is to date no reported treatment experience with this drug in such tumors …